Healthcare & Health Industry Wire — Week of July 7, 2026

Commure's new Orchestrator launch puts a specific number on a familiar access problem: 35% to 50% of medical referrals never lead to a completed specialist visit, and completed referrals take 31 days on average. The company's pitch is that artificial intelligence (AI) should move beyond note-taking and into the administrative path between referral, insurance verification, scheduling, and intake. 1

Commure launched Commure Orchestrator, an AI-powered platform for referral management and patient intake across inpatient, outpatient, post-acute, home health, hospice, and specialty care settings. The platform ingests unstructured referral data, extracts clinical and payer fields, validates the referral against an organization's rules, coordinates work in a dashboard queue, and writes accepted referrals back to the electronic health record. 1

For health systems, the operational bet is narrower than the AI hype cycle: fewer faxes, fewer dropped referrals, cleaner intake data, and less staff time spent re-keying insurance and clinical information. The article also notes Commure's recent capital base, including a $70 million May financing at a $7 billion valuation and a $200 million raise a year earlier, which gives the company room to sell a broader administrative platform rather than a single-point tool. 1

Why it matters: referral leakage is both a revenue-cycle problem and a care-access problem. If a system can see where referrals stall before the visit, the metric to watch is not only automation volume; it is whether more patients actually complete the appointment.

The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Casgevy, also known as exagamglogene autotemcel, for patients age 2 and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia. The agency said this is the first gene therapy approved for patients as young as age 2 with sickle cell disease. 2

Casgevy uses a patient's own blood-forming stem cells, edited with CRISPR/Cas9 gene-editing technology, and is given after full myeloablative conditioning, a high-intensity preparatory treatment used before stem cell transplant or gene therapy. In sickle cell disease, the treatment is intended to increase fetal hemoglobin, which helps prevent red blood cells from sickling. 2

The pediatric evidence base is still small, which matters for clinicians and families weighing timing. The FDA said 11 patients age 5 to under 12 with sickle cell disease were evaluated for safety and effectiveness; all eight patients evaluable for efficacy had no protocol-defined severe vaso-occlusive crises for at least 12 consecutive months within the first 24 months after infusion. For transfusion-dependent beta thalassemia, eight of nine efficacy-evaluable patients age 5 to under 12 achieved transfusion independence for 12 consecutive months, with a median transfusion-independence duration of 20.1 months. 2

The FDA granted the decision 53 days after filing and awarded approval to Vertex Pharmaceuticals. 2

The Centers for Medicare & Medicaid Services (CMS) issued the calendar year 2027 proposed rule for the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) payment system on July 2. CMS says the rule would affect about 3,500 hospitals and about 6,400 ASCs. 3

CMS proposes a 2.4% update to outpatient hospital and ASC payment rates for providers that meet applicable quality-reporting requirements. The rate is based on a 3.2% market-basket increase minus a 0.8 percentage-point productivity adjustment. 3

The larger policy fight is 340B. CMS proposes paying for 340B-acquired drugs at average sales price minus 33.4%, citing a 2026 hospital drug acquisition cost survey. CMS estimates the policy would reduce Original Medicare drug payments by $4.55 billion and beneficiary drug payments by $1.15 billion in the first year, while increasing OPPS payments for non-drug services by an equivalent amount because of budget-neutrality rules. 3

Hospitals also face a faster 340B remedy offset. CMS proposes increasing the annual reduction to non-drug OPPS payments from 0.5% to 3% in 2027, with the agency estimating that the repayment target will be reached in 2029. 3 HFMA's read is that the package could leave most hospitals with a negative net impact once the various cuts and increases are combined. 4

CMS is also proposing site-neutral payment for imaging-without-contrast services at certain off-campus hospital outpatient departments. CMS estimates first-year reductions of about $190 million in Part B spending, $70 million in beneficiary premiums, and $70 million in beneficiary cost-sharing. 3

Allegheny Health Network, part of Highmark Health, completed its acquisition of Heritage Valley Health System after regulators approved the deal. Heritage Valley operates two western Pennsylvania hospitals plus clinics and outpatient facilities. 5

The parties announced a commitment of about $285 million over the next decade for clinical-service expansion, facility improvements, and information technology. Allegheny said Heritage Valley's roughly 3,000 workers will become system employees, and the two hospitals, Heritage Valley Beaver and Heritage Valley Sewickley, will be renamed AHN Beaver Hospital-Heritage Valley and AHN Sewickley Hospital-Heritage Valley. 5

The financial context explains why this is more than a footprint expansion. Chief Healthcare Executive reported that Heritage Valley had faced financial challenges, including the closure of Kennedy Hospital and a Fitch Ratings downgrade last year tied to losses. 5

The Casgevy approval is a treatment milestone, but families do not start with gene therapy. They start with knowing whether a child has sickle cell disease or sickle cell trait, and whether parents or future siblings may be carriers.

CDC says sickle cell disease is often found at birth in the United States through routine newborn screening, and children with the disease need early diagnosis and treatment because of infection and other health risks. 6 The National Heart, Lung, and Blood Institute says all 50 states have newborn-screening programs, and follow-up teams contact families when a child's results suggest sickle cell disease; newborn screening can also identify sickle cell trait, where genetic counseling is offered. 7

If your baby's newborn screen shows possible sickle cell trait, Health Resources and Services Administration guidance says the child may need follow-up blood testing or genetic testing, and genetic counselors can help families understand future pregnancy risk. If both parents have sickle cell trait, HRSA says each pregnancy has a 1 in 4 chance of producing a child with S,S disease and a 1 in 2 chance of producing a child with sickle cell trait. 8

Action for patients and families: keep a copy of newborn-screening and follow-up hemoglobin test results, ask the pediatrician whether the result means disease or trait, and ask whether parents or siblings should be tested before future pregnancy planning. That is practical even if gene therapy is never needed; it turns a one-time infant lab result into useful family health information.